feedback

Course Director

Kurt Schalper, MD, PhD
Kurt Schalper, MD, PhD

Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

Faculty

Sanjay Mukhopadhyay
Sanjay Mukhopadhyay, MD

Cleveland Clinic
Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland, Ohio

Sandip Patel
Sandip Patel, MD

San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers.

This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer.

Target Audience

This activity has been designed to meet the educational needs of pathologists, oncologists, and other clinicians involved in the management of precision cancer immunotherapy and immunotherapy biomarkers and/or involved in cancer immunotherapy biomarker testing and treatment individualization.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies
  • Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances
  • Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings
  • Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology

Providership, Credit, and Support


This CME/MOC/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Certification Statement

ABPath CCThe activity titled "Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists" has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology's (ABPath) Continuing Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Kurt Schalper, MD, PhD
Assistant Professor of Pathology and Medicine
Yale School of Medicine
Director Translational Immuno-oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

Kurt Schalper, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clínica Alemana de Santiago; Dynamo Therapeutics, Inc.; EMD Serono, Inc.; Merck & Co., Inc.; Moderna, Inc.; Pierre Fabre Group; Shattuck Labs, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Torque Therapeutics.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck & Co., Inc.; Moderna, Inc.; Navigate BioPharma Services, Inc.; Pierre Fabre Group; Ribon Therapeutics, Inc.; Surface Oncology; Takeda Pharmaceuticals U.S.A., Inc.; and Tesaro, Inc/GlaxoSmithKline.
Speakers Bureau participant with Bristol Myers Squibb; Fluidigm Corporation; and Merck & Co., Inc.

Presenters
Sanjay Mukhopadhyay, MD
Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland, Ohio

Sanjay Mukhopadhyay, MD, has no financial interests/relationships or affiliations in relation to this activity.

Sandip Patel, MD
Associate Professor
Co-Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
Director, Clinical Trials Office
Division of Hematology and Oncology, Department of Medicine
UC San Diego Moores Cancer Center
La Jolla, California

Sandip Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; Illumina, Inc.; Paradigm Biopharmaceuticals Ltd; Rakuten Medical Inc.; and Tempus.
Grant/Research Support from AstraZeneca/MedImmune; Bristol Myers Squibb; Eli Lilly and Company; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Genocea Biosciences, Inc.; Incyte; Iovance Biotherapeutics, Inc.; Merck & Co., Inc.; Pfizer Inc; and Xcovery (Funding to University).

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Jim Zhai, MD, FCAP
Amita B. Patel, MSN, RN, AOCNP, NP-C

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC/CC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC/CC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.